Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alx Oncology Holdings (ALXO) Capital Expenditures (2019 - 2026)

Alx Oncology Holdings' Capital Expenditures history spans 5 years, with the latest figure at $148000.0 for Q4 2023.

  • On a quarterly basis, Capital Expenditures fell 61.95% to $148000.0 in Q4 2023 year-over-year; TTM through Dec 2023 was $1.3 million, a 10.72% decrease, with the full-year FY2025 number at $212000.0, down 52.57% from a year prior.
  • Capital Expenditures hit $148000.0 in Q4 2023 for Alx Oncology Holdings, up from -$1.3 million in the prior quarter.
  • Over the last five years, Capital Expenditures for ALXO hit a ceiling of $1.9 million in Q2 2020 and a floor of -$1.9 million in Q3 2020.
  • Historically, Capital Expenditures has averaged $208500.0 across 5 years, with a median of $224500.0 in 2022.
  • Biggest five-year swings in Capital Expenditures: skyrocketed 8314.29% in 2022 and later plummeted 778.65% in 2023.
  • Tracing ALXO's Capital Expenditures over 5 years: stood at -$62000.0 in 2019, then soared by 117.74% to $11000.0 in 2020, then skyrocketed by 2272.73% to $261000.0 in 2021, then surged by 49.04% to $389000.0 in 2022, then tumbled by 61.95% to $148000.0 in 2023.
  • Business Quant data shows Capital Expenditures for ALXO at $148000.0 in Q4 2023, -$1.3 million in Q3 2023, and $1.7 million in Q2 2023.